HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
EYE ON CHINA
Zhifei Biological's vaccine approved for clinical test
Chongqing Zhifei Biological Product Co., Ltd. got the approval documents for clinical test of its Mycobacterium Vaccae for Injection (Vaccae) from the SFDA (State Food and Drug Administration).

According to the approval documents, the product could be used as a biological product in Phase III clinical test for the prevention of tuberculosis.

As a product independently-developed and sold by Zhifei Biological, Vaccae could be used as adjuvant drug for the chemotherapy of tuberculosis. The product generated income of CNY 36.64 million, CNY 46.01 million and CNY 41.36 million in 2010, 2011 and the first three quarters of 2012, respectively, with an average gross profit margin of about 89.24%.

According to the 2012 global tuberculosis report issued by the WHO (World Health Organization), a total of 13 vaccines for the prevention of tuberculosis in the world have entered clinical research stage and only India's M.indicus pranii (MIP),which is still being developed, has entered Phase III clinical test stage. According to Zhifei Biological, the approval of the Vaccae to be used in Phase III clinical test means China has caught up with other countries in the study in this field.

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Eye Care/ Eye Health
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Diabetics Technology
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy